IL275238A - תרכובת נוזלית המכילה vegf אנטגוניסטי - Google Patents

תרכובת נוזלית המכילה vegf אנטגוניסטי

Info

Publication number
IL275238A
IL275238A IL275238A IL27523820A IL275238A IL 275238 A IL275238 A IL 275238A IL 275238 A IL275238 A IL 275238A IL 27523820 A IL27523820 A IL 27523820A IL 275238 A IL275238 A IL 275238A
Authority
IL
Israel
Prior art keywords
liquid composition
vegf antagonist
vegf
antagonist
composition
Prior art date
Application number
IL275238A
Other languages
English (en)
Other versions
IL275238B2 (he
IL275238B1 (he
Original Assignee
Samsung Bioepis Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samsung Bioepis Co Ltd filed Critical Samsung Bioepis Co Ltd
Publication of IL275238A publication Critical patent/IL275238A/he
Publication of IL275238B1 publication Critical patent/IL275238B1/he
Publication of IL275238B2 publication Critical patent/IL275238B2/he

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/49Platelet-derived growth factor [PDGF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/32Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL275238A 2017-12-22 2018-12-18 תרכובת נוזלית המכילה vegf אנטגוניסטי IL275238B2 (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170178693 2017-12-22
PCT/KR2018/016156 WO2019124946A1 (ko) 2017-12-22 2018-12-18 Vegf 길항제를 포함하는 액상 조성물

Publications (3)

Publication Number Publication Date
IL275238A true IL275238A (he) 2020-07-30
IL275238B1 IL275238B1 (he) 2023-08-01
IL275238B2 IL275238B2 (he) 2023-12-01

Family

ID=66994837

Family Applications (1)

Application Number Title Priority Date Filing Date
IL275238A IL275238B2 (he) 2017-12-22 2018-12-18 תרכובת נוזלית המכילה vegf אנטגוניסטי

Country Status (11)

Country Link
US (1) US20200390693A1 (he)
EP (1) EP3730126A4 (he)
JP (2) JP2021508687A (he)
KR (2) KR20230021164A (he)
CN (1) CN111556744B (he)
AU (1) AU2018388301B2 (he)
BR (1) BR112020012399A2 (he)
CA (2) CA3189025A1 (he)
IL (1) IL275238B2 (he)
TW (1) TW202023603A (he)
WO (1) WO2019124946A1 (he)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020022610A2 (pt) 2018-05-10 2021-02-09 Regeneron Pharmaceuticals, Inc. proteína de fusão de receptor de vegf de alta concentração que contém formulações
KR20220013343A (ko) * 2020-07-24 2022-02-04 (주) 팬젠 안과용 액상 조성물
CA3190325A1 (en) * 2020-07-31 2022-02-03 Celltrion Inc. Stable pharmaceutical preparation
TWI831202B (zh) * 2022-05-13 2024-02-01 新源生物科技股份有限公司 血管內皮生長因子受體融合蛋白醫藥組合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2633574T3 (es) * 2005-03-25 2017-09-22 Regeneron Pharmaceuticals, Inc. Formulaciones de antagonistas de VEGF
AU2012202859B2 (en) * 2006-06-16 2014-12-04 Regeneron Pharmaceuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
US7608261B2 (en) * 2006-06-16 2009-10-27 Regeneron Pharmacuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
CN103816115B (zh) * 2010-08-31 2017-06-27 成都康弘生物科技有限公司 一种含有抑制血管增生的融合蛋白的药物组合物及用途
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
BR112014009031A2 (pt) * 2011-10-18 2017-05-09 Coherus Biosciences Inc formulações de etanercept estabilizadas com íons de metais
EP2855030B1 (en) * 2012-06-01 2019-08-21 SurModics, Inc. Apparatus and method for coating balloon catheters
AR095396A1 (es) * 2013-03-13 2015-10-14 Genentech Inc Formulaciones de anticuerpo
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
KR101808234B1 (ko) * 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
CN109152831A (zh) * 2015-12-29 2019-01-04 安口生物公司 贝伐珠单抗的缓冲制剂
CN116327963A (zh) * 2016-11-21 2023-06-27 济世-伊沃泰克生物制品有限公司 一种眼科制剂及其用途
BR112020022610A2 (pt) * 2018-05-10 2021-02-09 Regeneron Pharmaceuticals, Inc. proteína de fusão de receptor de vegf de alta concentração que contém formulações

Also Published As

Publication number Publication date
US20200390693A1 (en) 2020-12-17
EP3730126A1 (en) 2020-10-28
BR112020012399A2 (pt) 2020-11-24
IL275238B2 (he) 2023-12-01
IL275238B1 (he) 2023-08-01
CN111556744B (zh) 2023-12-29
JP2021508687A (ja) 2021-03-11
KR102494021B1 (ko) 2023-02-06
EP3730126A4 (en) 2021-11-03
WO2019124946A1 (ko) 2019-06-27
JP2022166159A (ja) 2022-11-01
CA3085158A1 (en) 2019-06-27
TW202023603A (zh) 2020-07-01
KR20200084897A (ko) 2020-07-13
CN111556744A (zh) 2020-08-18
AU2018388301A1 (en) 2020-07-02
CA3085158C (en) 2023-04-04
KR20230021164A (ko) 2023-02-13
AU2018388301B2 (en) 2022-02-17
CA3189025A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
GB201520014D0 (en) Liquid formulation
ZA201901590B (en) Liquid pharmaceutical composition
EP3476386C0 (en) LIQUID PHARMACEUTICAL COMPOSITION
ZA201901736B (en) Liquid pharmaceutical composition
IL275238A (he) תרכובת נוזלית המכילה vegf אנטגוניסטי
IL258892B (he) אנטגוניסטים לקולטן פפטיד קשור-גן קלציטונין
HK1257026A1 (zh) 液體藥物組合物
HK1231391A1 (zh) 液體藥物組合物
HK1245816B (zh) 導電性液狀組合物
HK1249095A1 (zh) Cgrp受體拮抗劑
IL258894A (he) אנטגוניסטים לקולטן פפטיד קשור-גן קלציטונין
IL258893A (he) אנטגוניסטים לקולטן פפטיד קשור-גן קלציטונין
HK1244685A1 (zh) 液體藥物組合物
ZA201902304B (en) Liquid detergent composition
IL252903B (he) פפטידיי אנטגוניסט cgrp
GB201505051D0 (en) Liquid formulation
IL268329B (he) תכשיר נוזלי המכיל פרדופלוקסאצין
EP3630933C0 (en) LIQUID DETERGENT COMPOSITION
IL253572A0 (he) תכשיר רוקחי נוזלי
ZA201704249B (en) Cgrp antagonist peptides
GB201616094D0 (en) Pharmacutical composition